Billions of people have succumbed to cancer. Since prehistory, the disease has been feared because of how deadly it is. Mankind had a hard time fighting the disease because of the limited resources that our ancestors have. However, as the human civilization progresses, scientists around the world are studying the possible cure for cancer. They are doing their best to eradicate the disease as soon as possible, and the scientists are working all together by publishing their researches on scientific journals, and sharing it among their colleagues. One of the most well-known scientific journals tackling about cancer is Oncotarget, a weekly publication being written by oncologists. Oncotarget has a massive collection of articles and studies focusing on cancer. It states the current condition of the disease, the development of the cure, and other related information about the disease. Oncotarget released its first issue in 2010, and it is published by Impact Journals. Dr. Mikhail Blagosklonny and Andrei V. Gudkov, both working at the Roswell Park Cancer Institute as scientists and oncologists – are the publication’s editors in chief.
Dr. Mikhail Blagosklonny is known in the field of oncology as the scientist who is working with a substance called rapamycin to develop a drug that will stop the aging process. His research was published through Oncotarget, and it gained the attention of scientists around the world because of its touch of science fiction. Scientists ridiculed his theory at first, but today, many are serious about the study’s development. Another article that was recently published in Oncotarget involves the research made at the Norris Cotton Cancer Center in Dartmouth, which states how cancer tumors can be identified and eradicated 100% from the patient’s body.
Scientists around the world are racing against time to create a cure for the dreaded disease. They are coordinating with one another by sharing information through Oncotarget. The scientific journal can be considered as a tool for delivering the information to the public, as the information posted on the journal can be viewed online for free. Dr. Mikhail Blagosklonny is recommending the journal to everyone, stating that it is essential for the people to know the developments about fighting cancer.